Vaxxinity Stock Analysis

VAXX Stock  USD 0.46  0.04  9.52%   
Vaxxinity is undervalued with Real Value of 3.09 and Target Price of 11.0. The main objective of Vaxxinity stock analysis is to determine its intrinsic value, which is an estimate of what Vaxxinity is worth, separate from its market price. There are two main types of Vaxxinity's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Vaxxinity's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Vaxxinity's stock to identify patterns and trends that may indicate its future price movements.
The Vaxxinity stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Vaxxinity is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Vaxxinity Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Vaxxinity's ongoing operational relationships across important fundamental and technical indicators.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxxinity. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
For more information on how to buy Vaxxinity Stock please use our How to Invest in Vaxxinity guide.

Vaxxinity Stock Analysis Notes

About 51.0% of the company outstanding shares are owned by insiders. The book value of Vaxxinity was at this time reported as 0.11. The company has Price/Earnings To Growth (PEG) ratio of 0.05. Vaxxinity recorded a loss per share of 0.45. The entity had not issued any dividends in recent years. Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas. Vaxxinity Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. For more information please call Mei JD at 254 244 5739 or visit

Vaxxinity Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Vaxxinity's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Vaxxinity or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Vaxxinity generated a negative expected return over the last 90 days
Vaxxinity has high historical volatility and very poor performance
Vaxxinity has some characteristics of a very speculative penny stock
Vaxxinity has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (56.93 M) with loss before overhead, payroll, taxes, and interest of (1.87 M).
Vaxxinity currently holds about 128.23 M in cash with (57.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Vaxxinity has a frail financial position based on the latest SEC disclosures
Roughly 51.0% of the company outstanding shares are owned by insiders
Latest headline from Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

Vaxxinity Upcoming and Recent Events

Earnings reports are used by Vaxxinity to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vaxxinity previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
25th of March 2024
Upcoming Quarterly Report
14th of May 2024
Next Financial Report
31st of December 2023
Next Fiscal Quarter End
25th of March 2024
Next Fiscal Year End
30th of September 2023
Last Quarter Report
31st of December 2022
Last Financial Announcement

Vaxxinity Largest EPS Surprises

Earnings surprises can significantly impact Vaxxinity's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Vaxxinity Thematic Classifications

In addition to having Vaxxinity stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Vaxxinity Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Vaxxinity is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vaxxinity backward and forwards among themselves. Vaxxinity's institutional investor refers to the entity that pools money to purchase Vaxxinity's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Pathstone Holdings Llc2023-12-31
153.8 K
Pathstone Family Office, Llc2023-09-30
153.8 K
Scoggin Llc2023-09-30
150 K
Bank Of New York Mellon Corp2023-12-31
120.7 K
Charles Schwab Investment Management Inc2023-12-31
120.3 K
Ieq Capital, Llc2023-12-31
83.3 K
Mcadam, Llc2023-12-31
78.3 K
Barclays Plc2023-12-31
58.5 K
Nuveen Asset Management, Llc2023-12-31
58 K
Adage Capital Partners Gp Llc2023-12-31
Blackrock Inc2023-12-31
2.7 M
Note, although Vaxxinity's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vaxxinity Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 58.91 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vaxxinity's market, we take the total number of its shares issued and multiply it by Vaxxinity's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Vaxxinity Profitablity

Vaxxinity's profitability indicators refer to fundamental financial ratios that showcase Vaxxinity's ability to generate income relative to its revenue or operating costs. If, let's say, Vaxxinity is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Vaxxinity's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Vaxxinity's profitability requires more research than a typical breakdown of Vaxxinity's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for Next Year
Return On Tangible Assets(1.28)(1.35)
Return On Capital Employed(2.18)(2.29)
Return On Assets(1.28)(1.35)
Return On Equity(4.25)(4.03)

Management Efficiency

Vaxxinity has return on total asset (ROA) of (0.4834) % which means that it has lost $0.4834 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5065) %, meaning that it created substantial loss on money invested by shareholders. Vaxxinity's management efficiency ratios could be used to measure how well Vaxxinity manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.35 in 2024. Return On Capital Employed is likely to drop to -2.29 in 2024. At this time, Vaxxinity's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 75.1 M in 2024, whereas Total Current Assets are likely to drop slightly above 31.6 M in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 0.11  0.09 
Net Current Asset Value 0.00  0.00 
Tangible Asset Value 0.00  0.00 
Tangible Book Value Per Share 0.11  0.09 
Enterprise Value Over EBITDA(2.10)(2.20)
Price Book Value Ratio 8.02  8.42 
Enterprise Value Multiple(2.10)(2.20)
Price Fair Value 8.02  8.42 
Enterprise Value135.3 M128.5 M
The analysis of Vaxxinity's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Vaxxinity's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Vaxxinity Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.

Technical Drivers

As of the 19th of April, Vaxxinity has the Variance of 27.13, risk adjusted performance of (0.06), and Coefficient Of Variation of (865.65). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vaxxinity, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We have analyzed and interpolated thirteen technical drivers for Vaxxinity, which can be compared to its competition. Please validate Vaxxinity market risk adjusted performance and treynor ratio to decide if Vaxxinity is priced more or less accurately, providing market reflects its prevalent price of 0.46 per share. As Vaxxinity is a penny stock we also advise to double-check its jensen alpha numbers.

Vaxxinity Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Vaxxinity middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Vaxxinity. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Vaxxinity Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vaxxinity insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vaxxinity's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vaxxinity insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Vaxxinity Predictive Daily Indicators

Vaxxinity intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vaxxinity stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Vaxxinity Forecast Models

Vaxxinity's time-series forecasting models are one of many Vaxxinity's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vaxxinity's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Vaxxinity Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Vaxxinity prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vaxxinity shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Vaxxinity. By using and applying Vaxxinity Stock analysis, traders can create a robust methodology for identifying Vaxxinity entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin-2.4 K-2.3 K
Operating Profit Margin-2.2 K-2.1 K
Net Loss-2.4 K-2.3 K
Gross Profit Margin(32.60)(30.97)

Current Vaxxinity Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vaxxinity analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vaxxinity analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
11.0Strong Buy1Odds
Vaxxinity current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Vaxxinity analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Vaxxinity stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Vaxxinity, talking to its executives and customers, or listening to Vaxxinity conference calls.
Vaxxinity Analyst Advice Details

Vaxxinity Stock Analysis Indicators

Vaxxinity stock analysis indicators help investors evaluate how Vaxxinity stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Vaxxinity shares will generate the highest return on investment. By understating and applying Vaxxinity stock analysis, traders can identify Vaxxinity position entry and exit signals to maximize returns.
Begin Period Cash Flow34.6 M
Long Term Debt13.3 M
Common Stock Shares Outstanding126.5 M
Total Stockholder Equity13.4 M
Property Plant And Equipment Net11.1 M
Cash And Short Term Investments30.5 M
Accounts Payable1.8 M
Net Debt10.1 M
50 Day M A0.6777
Total Current Liabilities17.6 M
Other Operating Expenses58.3 M
Non Current Assets Total11.1 M
Stock Based Compensation7.5 M
When determining whether Vaxxinity offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vaxxinity's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vaxxinity Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vaxxinity Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxxinity. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
For more information on how to buy Vaxxinity Stock please use our How to Invest in Vaxxinity guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Vaxxinity Stock analysis

When running Vaxxinity's price analysis, check to measure Vaxxinity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxxinity is operating at the current time. Most of Vaxxinity's value examination focuses on studying past and present price action to predict the probability of Vaxxinity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxxinity's price. Additionally, you may evaluate how the addition of Vaxxinity to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Is Vaxxinity's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vaxxinity. If investors know Vaxxinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vaxxinity listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Quarterly Revenue Growth
Return On Assets
Return On Equity
The market value of Vaxxinity is measured differently than its book value, which is the value of Vaxxinity that is recorded on the company's balance sheet. Investors also form their own opinion of Vaxxinity's value that differs from its market value or its book value, called intrinsic value, which is Vaxxinity's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vaxxinity's market value can be influenced by many factors that don't directly affect Vaxxinity's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vaxxinity's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vaxxinity is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vaxxinity's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.